Key result
Application of 5 mM 4-aminopyridine, 100 microM flecainide, or 500 microM cadmium reduced A-type current amplitude in human neocortical neurons by 35%, 22%, and 31%, respectively.
Neocortical neurons from epilepsy patients express an A-type current with electrophysiological and pharmacological properties similar to those described in animal tissues.
Supports A-type current similarity in human epilepsy neurons to animal models; extends cross-species data but leaves open clinical translation.
A-type currents powerfully modulate discharge behavior and have been described in a large number of different species and cell types. However, data on A-type currents in human brain tissue are scarce. Here we have examined the properties of a fast transient outward current in acutely dissociated human neocortical neurons from the temporal lobe of epilepsy patients by using the whole-cell voltage-clamp technique. The A-type current was isolated with a subtraction protocol. In addition, delayed potassium currents were reduced pharmacologically with 10 mM tetraethylammonium chloride. The current displayed an activation threshold of about -70 mV. The voltage-dependent activation was fitted with a Boltzmann function, with a half-maximal conductance at -14.8 +/- 1.8 mV (n = 5) and a slope factor of 17.0 +/- 0.5 mV (n = 5). The voltage of half-maximal steady-state inactivation was -98.9 +/- 8.3 mV (n = 5), with a slope factor of -6.6 +/- 1.9 mV (n = 5). Recovery from inactivation could be fitted monoexponentially with a time constant of 18.2 +/- 7.5 msec (n = 5). At a command potential of +30 mV, application of 5 mM 4-aminopyridine or 100 microM flecainide resulted in a reduction of A-type current amplitude by 35% or 22%, respectively. In addition, flecainide markedly accelerated inactivation. Current amplitude was reduced by 31% with application of 500 microM cadmium. All drug effects were reversible. In conclusion, neocortical neurons from epilepsy patients express an A-type current with properties similar to those described for animal tissues.
No takes yet. Share an insight, caveat, or question.
Rüschenschmidt et al. (2004) studied Epilepsy (n=5). Pharmacological agents (4-aminopyridine, flecainide, cadmium) was evaluated on Reduction of A-type current amplitude. Application of 5 mM 4-aminopyridine, 100 microM flecainide, or 500 microM cadmium reduced A-type current amplitude in human neocortical neurons by 35%, 22%, and 31%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: